Osteoporosis medication prescribing in British Columbia and Ontario: Impact of public drug coverage

Osteoporosis International

Volumn 23, Issue 4, 2012, Pages 1475-1480

  Cadarette, S M ^a,b   Carney, G ^c   Baek, D ^a   Gunraj, N ^b   Paterson, J M ^a,b,d,e   Dormuth, C R ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e CENTRE FOR EVALUATION OF MEDICINES   (Canada)

Author keywords

Drug policy; Osteoporosis; Pharmacotherapy

Indexed keywords

ALENDRONIC ACID; CALCITONIN; DENOSUMAB; ETIDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

AGED; ARTICLE; CANADA; FEMALE; HUMAN; MALE; OSTEOPOROSIS; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; CLINICAL PRACTICE; COMPARATIVE STUDY; DRUG UTILIZATION; INSURANCE; NATIONAL HEALTH SERVICE; POSTMENOPAUSE OSTEOPOROSIS; SEX DIFFERENCE; STATISTICS;

AGED; BONE DENSITY CONSERVATION AGENTS; BRITISH COLUMBIA; DIPHOSPHONATES; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; HUMANS; INSURANCE COVERAGE; MALE; ONTARIO; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PHYSICIAN'S PRACTICE PATTERNS; SEX FACTORS; STATE MEDICINE;

EID: 84861751037     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1771-2     Document Type: Article

References (11)

1. Papaioannou A, Morin S, Cheung AM et al (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. Can Med Assoc J 182:1864-1873
2. MacLean C, Newberry S, Maglione M et al (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148:197-213
3. Cranney A, Guyatt G, Griffith L et al (2002) IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570-578
4. Osteoporosis Canada Provincial Drug Coverage Chart. http://www. osteoporosis.ca/index.php/ci-id/9046/la-id.htm. Accessed 11 Jan 2011
5. Ontario Ministry of Health and Long-Term Care Formulary Search: Ontario Drug Benefit Formulary/Comparative Drug Index. https://www.healthinfo.moh.gov. on.ca/formulary/index.jsp. Accessed 11 Jan 2011
6. Cadarette SM, Jaglal SB, Raman-Wilms L, Beaton DE, Paterson JM (2011) Osteoporosis quality indicators using healthcare utilization data. Osteoporos Int 22:1335-1342
7. Brown JP, Josse RG, Scientific Advisory Council of the Osteoporosis Society of Canada (2002) 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 167(10 SUPPL.):S1-S34
8. Brown JP, Fortier M, Frame H et al (2006) Canadian consensus conference on osteoporosis, 2006 update. J Obstet Gynaecol Can 28:S95-S112
9. Scientific Advisory Board, Osteoporosis Society of Canada (1996) Clinical practice guidelines for the diagnosis and management of osteoporosis. Can Med Assoc J 155:1113-1133
10. Mamdani M, Kopp A, Hawker G (2007) Hip fractures in users of first-vs. second-generation bisphosphonates. Osteoporos Int 18:1595-1600
11. Health Canada Notice of compliance (NOC) online query. http://webprod3.hc-sc.gc.ca/noc-ac/index-eng.jsp. Accessed 12 April 2011